EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Acetaminophen for Prevention and Treatment of Organ Dysfunction in Critically Ill Patients With Sepsis

Lorraine B Ware, D Clark Files, Alpha Fowler, Michael S Aboodi, Neil R Aggarwal, Roy G Brower, Steven Y Chang, Ivor S Douglas, Scott Fields, Andrea S Foulkes, Adit A Ginde, Estelle S Harris und 8 weitere

JAMA · 06.08.2024 · 332 (5) · 390

DOI: 10.1001/jama.2024.8772 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift JAMA, erschienen am 06.08.2024. Verfasst von Lorraine B Ware und 19 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt University Medical Center, Nashville, Tennessee. Hauptthemen laut MEDLINE: Acetaminophen, Analgesics, Non-Narcotic, Critical Illness, Multiple Organ Failure. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Acetaminophen (paracetamol) has many pharmacological effects that might be beneficial in sepsis, including inhibition of cell-free hemoglobin-induced oxidation of lipids and other substrates.

Objective

To determine whether acetaminophen increases days alive and free of organ dysfunction in sepsis compared with placebo. Design, Setting, and Participants Phase 2b randomized, double-blind, clinical trial conducted from October 2021 to April 2023 with 90-day follow-up. Adults with sepsis and respiratory or circulatory organ dysfunction were enrolled in the emergency department or intensive care unit of 40 US academic hospitals within 36 hours of presentation.

Intervention

Patients were randomized to 1 g of acetaminophen intravenously every 6 hours or placebo for 5 days. Main Outcome and Measures The primary end point was days alive and free of organ support (mechanical ventilation, vasopressors, and kidney replacement therapy) to day 28. Treatment effect modification was evaluated for acetaminophen by prerandomization plasma cell-free hemoglobin level higher than 10 mg/dL.

Results

Of 447 patients enrolled (mean age, 64 [SD, 15] years, 51% female, mean Sequential Organ Failure Assessment [SOFA] score, 5.4 [SD, 2.5]), 227 were randomized to acetaminophen and 220 to placebo. Acetaminophen was safe with no difference in liver enzymes, hypotension, or fluid balance between treatment arms. Days alive and free of organ support to day 28 were not meaningfully different for acetaminophen (20.2 days; 95% CI, 18.8 to 21.6) vs placebo (19.6 days; 95% CI, 18.2 to 21.0; P = .56; difference, 0.6; 95% CI, −1.4 to 2.6). Among 15 secondary outcomes, total, respiratory, and coagulation SOFA scores were significantly lower on days 2 through 4 in the acetaminophen arm as was the rate of development of acute respiratory distress syndrome within 7 days (2.2% vs 8.5% acetaminophen vs placebo; P = .01; difference, −6.3; 95% CI, −10.8 to −1.8). There was no significant interaction between cell-free hemoglobin levels and acetaminophen. Conclusions and Relevance Intravenous acetaminophen was safe but did not significantly improve days alive and free of organ support in critically ill sepsis patients. Trial Registration ClinicalTrials.gov Identifier: NCT04291508

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcetaminophenAnalgesics, Non-NarcoticCritical IllnessMultiple Organ FailureOrgan Dysfunction ScoresSepsisAgedFemaleHumansMaleMiddle AgedDouble-Blind MethodHemoglobinsRenal Replacement TherapyRespiration, ArtificialInfusions, Intravenous

Substanzen

AcetaminophenAnalgesics, Non-NarcoticHemoglobins

Autor:innen und Institutionen

  • Vanderbilt University Medical Center, Nashville, Tennessee.
  • Wake Forest University, Winston Salem, North Carolina.
  • Viginia Commonwealth University, Richmond.
  • Montefiore Medical Center, New York, New York.
  • University of Colorado School of Medicine, Aurora.
  • Johns Hopkins University, Baltimore, MD.

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Ware, L. B., Files, D. C., Fowler, A., Aboodi, M. S., Aggarwal, N. R., Brower, R. G., Chang, S. Y., Douglas, I. S., Fields, S., Foulkes, A. S., Ginde, A. A., Harris, E. S., Hendey, G. W., Hite, R. D., Huang, W., Lai, P., Liu, K. D., Thompson, B. T., Matthay, M. A., & National Heart, Lung, and Blood Institute Prevention and Early Treatment of Acute Lung Injury Clinical Trials Network (2024). Acetaminophen for Prevention and Treatment of Organ Dysfunction in Critically Ill Patients With Sepsis. JAMA, 332(5), 390. https://doi.org/10.1001/jama.2024.8772

Vancouver

Ware LB, Files DC, Fowler A, Aboodi MS, Aggarwal NR, Brower RG, et al. Acetaminophen for Prevention and Treatment of Organ Dysfunction in Critically Ill Patients With Sepsis. JAMA. 2024;332(5):390. doi:10.1001/jama.2024.8772

BibTeX
@article{Ware2024,
  author = {Ware, Lorraine B and Files, D Clark and Fowler, Alpha and Aboodi, Michael S and Aggarwal, Neil R and Brower, Roy G and Chang, Steven Y and Douglas, Ivor S and Fields, Scott and Foulkes, Andrea S and Ginde, Adit A and Harris, Estelle S and Hendey, Gregory W and Hite, R Duncan and Huang, Weixing and Lai, Poying and Liu, Kathleen D and Thompson, B Taylor and Matthay, Michael A and National Heart, Lung, and Blood Institute Prevention and Early Treatment of Acute Lung Injury Clinical Trials Network, National Heart, Lung, and Blood Institute Prevention and Early Treatment of Acute Lung Injury Clinical Trials Network},
  title = {Acetaminophen for Prevention and Treatment of Organ Dysfunction in Critically Ill Patients With Sepsis},
  journal = {JAMA},
  year = {2024},
  volume = {332},
  number = {5},
  pages = {390},
  doi = {10.1001/jama.2024.8772}
}
Kostenlos starten →